{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:10:23Z","timestamp":1788030623490,"version":"build-2784847793"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vph.2016.03.003","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T18:53:45Z","timestamp":1458154425000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2016.03.003_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes","volume":"83","author":"Davies","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.vph.2016.03.003_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vph.2016.03.003_bb0015","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0020","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe \u2014 epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2003.10.006","article-title":"Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE])","volume":"93","author":"Goldberg","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2016.03.003_bb0030","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.amjmed.2014.12.007","article-title":"Late consequences of acute coronary syndromes: Global Registry Of Acute Coronary Events (GRACE) follow-up","volume":"128","author":"Alnasser","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0035","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1076029612472551","article-title":"Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome","volume":"20","author":"White","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0040","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2009.03.013","article-title":"Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis","volume":"53","author":"Brar","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.03.003_bb0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1172\/JCI13361","article-title":"ADP and platelets: the end of the beginning","volume":"107","author":"Woulfe","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2016.03.003_bb0055","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1378\/chest.124.3_suppl.18S","article-title":"Thrombin and platelet activation","volume":"124","author":"Brass","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.vph.2016.03.003_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH09-03-0192","article-title":"Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis","volume":"102","author":"Jennings","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0065","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"General mechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC Working Group on thrombosis\u2013task force on anticoagulants in heart disease","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of tissue factor in hemostasis, thrombosis, and vascular development","volume":"24","author":"Mackman","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2016.03.003_bb0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0080","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2016.03.003_bb0085","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.124.3_suppl.4S","article-title":"Thrombin formation","volume":"124","author":"Mann","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.vph.2016.03.003_bb0090","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0095","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0100","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0105","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.03.003_bb0110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0115","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0130","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0140","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1538-7836.2007.02799.x","article-title":"Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition","volume":"6","author":"Brummel-Ziedins","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0155","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2002-03-0954","article-title":"Coagulation activation and long-term outcome in acute coronary syndromes","volume":"102","author":"Ardissino","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.vph.2016.03.003_bb0160","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0170","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0175","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0185","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0190","unstructured":"Goldstein. Safety evaluation of the factor Xa inhibitor TAK-442 in subjects with acute coronary syndromes: phase 2 AXIOM-ACS trial results. http:\/\/spo.escardio.org\/SessionDetails.aspx?eevtid=48&sessId=8199&subSessId=1307&searchQuery=&presId=59578&doc=Abstract#.UwnlCr9BpqM. (Accessed March 6 2017)."},{"key":"10.1016\/j.vph.2016.03.003_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0200","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.vph.2016.03.003_bb0210","unstructured":"AstraZeneca decides to withdraw Exanta\u2122. (Available at: http:\/\/www.clotcare.com\/astrazenecapullsexanta.aspx. Accessed March 6 2017)."},{"key":"10.1016\/j.vph.2016.03.003_bb0215","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0225","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jacc.2013.01.066","volume":"61","author":"Mega","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.03.003_bb0230","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1160\/TH13-07-0543","article-title":"Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome","volume":"111","author":"Goldstein","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0235","unstructured":"Bayer Pharma AG. Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed March 6 2016."},{"key":"10.1016\/j.vph.2016.03.003_bb0240","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0245","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0255","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","article-title":"Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease","volume":"31","author":"Goto","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0260","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary Syndromes trial","volume":"123","author":"O'Donoghue","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0265","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","article-title":"Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial","volume":"123","author":"Wiviott","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0270","unstructured":"Food and Drug Administration. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. (Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm396585.htm. Accessed March 6 2016)."},{"key":"10.1016\/j.vph.2016.03.003_bb0275","author":"Merck Sharp & Dohme Inc"},{"key":"10.1016\/j.vph.2016.03.003_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2016.03.003_bb0285","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0290","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/0003319711427391","article-title":"Prognostic significance of prevalent and incident atrial fibrillation among patients hospitalized with acute coronary syndrome: findings from the Gulf RACE-2 Registry","volume":"63","author":"Hersi","year":"2012","journal-title":"Angiology"},{"key":"10.1016\/j.vph.2016.03.003_bb0295","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000382","article-title":"New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study","volume":"3","author":"Bang","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.vph.2016.03.003_bb0300","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0305","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0310","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0315","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.03.003_bb0320","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1160\/TH11-04-0262","article-title":"Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective","volume":"106","author":"Faxon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0325","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0330","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0335","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.crvasa.2014.03.001","article-title":"The WOEST study: critical considerations and applicability","volume":"56","author":"Rubboli","year":"2014","journal-title":"Cor Vasa"},{"key":"10.1016\/j.vph.2016.03.003_bb0340","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.03.003_bb0345","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0350","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(15)60213-6","article-title":"Clinical evidence for oral antiplatelet therapy in acute coronary syndromes","volume":"386","author":"Wiviott","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0355","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.03.003_bb0360","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.vph.2016.03.003_bb0365","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0370","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0375","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.03.003_bb0380","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.03.003_bb0385","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1160\/TH14-08-0681","article-title":"The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview","volume":"112","author":"Rubboli","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.03.003_bb0390","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jacc.2014.10.063","article-title":"Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet","volume":"65","author":"Capodanno","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.03.003_bb0395","unstructured":"Janssen Scientific Affairs LLC. A study exploring two strategies of rivaroxaban and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). (Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01830543. Accessed March 6 2016)."},{"key":"10.1016\/j.vph.2016.03.003_bb0400","unstructured":"Boehringer Ingelheim. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI). (Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02164864. Accessed March 6 2016)."},{"key":"10.1016\/j.vph.2016.03.003_bb0405","unstructured":"Bristol-Myers Squibb. Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome\/Percutaneous Coronary Intervention. (Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415400. Accessed March 6 2016)."},{"key":"10.1016\/j.vph.2016.03.003_bb0410","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115301178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115301178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T12:28:56Z","timestamp":1567686536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115301178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":82,"alternative-id":["S1537189115301178"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2016.03.003","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2016.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}